kr411.60
0.56% today
Copenhagen, Nov 17, 02:46 pm CET
ISIN
DK0060336014
Symbol
NSIS B
Sector
Industry

Novonesis Stock price

kr413.90
+14.80 3.71% 1M
-27.20 6.17% 6M
+6.20 1.52% YTD
+6.80 1.67% 1Y
+0.00 0.00% 3Y
+41.60 11.17% 5Y
+91.10 28.22% 10Y
+349.70 544.70% 20Y
Copenhagen, Closing price Fri, Nov 14 2025
-5.80 1.38%
ISIN
DK0060336014
Symbol
NSIS B
Sector
Industry

New AI Insights on Novonesis Insights AI Insights on Novonesis

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
kr195.4b
Enterprise Value
kr216.3b
Net debt
kr20.9b
Cash
kr2.3b
Shares outstanding
465.7m
Valuation (TTM | estimate)
P/E
36.8 | 29.4
P/S
5.1 | 6.2
EV/Sales
5.6 | 6.9
EV/FCF
31.2
P/B
2.4
Dividends
DPS
kr6.20
Yield 1Y | 5Y
1.5% | 1.5%
Growth 1Y | 5Y
0.0% | 3.4%
Payout 1Y | 3Y
124.8% | 63.3%
Increased
0 Years
Financials (TTM | estimate)
Revenue
kr38.6b | kr31.5b
EBITDA
- | kr11.7b
EBIT
kr8.4b | kr7.9b
Net Income
kr5.2b | kr6.6b
Free Cash Flow
kr6.9b
Growth (TTM | estimate)
Revenue
- | 10.1%
EBITDA
- | 86.0%
EBIT
- | 61.3%
Net Income
- | 187.4%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
52.8%
EBITDA
- | 37.2%
EBIT
21.9%
Net
13.6% | 20.8%
Free Cash Flow
18.0%
Financial Health
Equity Ratio
73.6%
Return on Equity
2.7%
ROCE
7.5%
ROIC
5.7%
Debt/Equity
0.3
More
EPS
kr11.3
FCF per Share
kr14.9
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Novonesis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Novonesis Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Novonesis forecast:

15x Buy
68%
5x Hold
23%
2x Sell
9%

Analyst Opinions

22 Analysts have issued a Novonesis forecast:

Buy
68%
Hold
23%
Sell
9%

Financial data from Novonesis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
38,564 38,564
-
100%
- Direct Costs 18,208 18,208
-
47%
20,356 20,356
-
53%
- Selling and Administrative Expenses 7,978 7,978
-
21%
- Research and Development Expense 4,140 4,140
-
11%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 8,442 8,442
-
22%
Net Profit 5,249 5,249
-
14%

In millions DKK.

Don't miss a Thing! We will send you all news about Novonesis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Head office Denmark
CEO Ester Baiget
Website www.novozymes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today